Vascodagama Online Journal

Choroideremia Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight | 4D Molecular Therapeutics, Roche, Biogen and Many Others

 Breaking News
  • No posts were found

Choroideremia Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight | 4D Molecular Therapeutics, Roche, Biogen and Many Others

October 01
22:09 2021
Choroideremia Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight | 4D Molecular Therapeutics, Roche, Biogen and Many Others
Choroideremia Pipeline

Choroideremia is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal pigment epithelium and retina. This disease is caused by mutations in the X-linked CHM gene encoding a Ras-related GTPase Rab escort protein (REP)-1, which is extremely important for the retinal function. Choroideremia is characterized by extensive loss of all retinal layers in the eyes.

 

DelveInsight’s, “Choroideremia Pipeline Insight, 2021” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Choroideremia pipeline landscapes. It comprises Choroideremia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Choroideremia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Choroideremia pipeline products.

 

Some of the key takeaways from the Choroideremia Pipeline Report 

  • Major companies such as NightstaRx Ltd/Biogen, 4D Molecular Therapeutics, Curative Biotech, Therapeutics, Spark therapeutics/Roche, and others are developing potential drug candidates to improve the Choroideremia treatment scenario. 
  •  In June 2021, NightstaRx Ltd announced that the results from Phase III did not satisfy the primary endpoint and secondary efficacy endpoints. Therefore, they will evaluate the results before confirming the next step of the study.
  • 4D therapeutics is developing and investigating its lead product candidate 4D-110 in an ongoing Phase I dose-escalation clinical trial in patients with choroideremia related to mutations in the CHM gene.
  • In February 2019, Roche entered into a definitive merger agreement to acquire Spark Therapeutics and its clinical assets, including SPK-7001 for choroideremia in Phase I/II.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

 

Some of Choroideremia Companies are:

  • 4D Molecular Therapeutics
  • Roche
  • Biogen
  • Curative Biotechnology
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight 

 

DelveInsight’s Choroideremia report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase II and Phase II/III)
  • Mid-stage products (Phase II and Phase II/III)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Choroideremia Therapies:

  • 4D-110
  • RG 6367
  • BIIB111
  • Metformin
  • And Many Others

 

Current Choroideremia Treatment Scenario and Choroideremia Emerging Therapies:

  • How many companies are developing Choroideremia drugs?
  • How many Choroideremia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Choroideremia?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Choroideremia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Choroideremia and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Choroideremia: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Choroideremia – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Choroideremia Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

BIIB111: Biogen

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

4D110: 4D Molecular therapeutics

Drug profiles in the detailed report…..

Preclinical stage products

• Comparative Analysis

Metformin: Curative Biotechnology

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Choroideremia Key Companies

Choroideremia Key Products

Choroideremia- Unmet Needs

Choroideremia- Market Drivers and Barriers

Choroideremia- Future Perspectives and Conclusion

Choroideremia Analyst Views

Choroideremia Key Companies

Appendix

 

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/choroideremia-pipeline-insight